Nothing Special   »   [go: up one dir, main page]

ATE291351T1 - Superoxiddismutase memetika - Google Patents

Superoxiddismutase memetika

Info

Publication number
ATE291351T1
ATE291351T1 AT94930729T AT94930729T ATE291351T1 AT E291351 T1 ATE291351 T1 AT E291351T1 AT 94930729 T AT94930729 T AT 94930729T AT 94930729 T AT94930729 T AT 94930729T AT E291351 T1 ATE291351 T1 AT E291351T1
Authority
AT
Austria
Prior art keywords
memetics
superoxide dismutase
relates
radicals
modulating
Prior art date
Application number
AT94930729T
Other languages
English (en)
Inventor
James D Crapo
Irwin Fridovich
Tim Oury
Brian J Day
Rodney J Folz
Bruce A Freeman
Original Assignee
Univ Duke
Univ Alabama Birmingham Res Fo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Univ Alabama Birmingham Res Fo filed Critical Univ Duke
Application granted granted Critical
Publication of ATE291351T1 publication Critical patent/ATE291351T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT94930729T 1993-10-15 1994-10-13 Superoxiddismutase memetika ATE291351T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13620793A 1993-10-15 1993-10-15
PCT/US1994/011558 WO1995010185A1 (en) 1993-10-15 1994-10-13 Superoxide dismutase and mimetics thereof

Publications (1)

Publication Number Publication Date
ATE291351T1 true ATE291351T1 (de) 2005-04-15

Family

ID=22471830

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94930729T ATE291351T1 (de) 1993-10-15 1994-10-13 Superoxiddismutase memetika

Country Status (9)

Country Link
US (1) US5747026A (de)
EP (2) EP1442747A1 (de)
JP (1) JPH09505805A (de)
AT (1) ATE291351T1 (de)
AU (1) AU702596B2 (de)
CA (1) CA2174236C (de)
DE (1) DE69434313T2 (de)
ES (1) ES2237753T3 (de)
WO (1) WO1995010185A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) * 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
WO1996009053A1 (en) * 1994-09-20 1996-03-28 Duke University Oxidoreductase activity of manganic porphyrins
JPH11509180A (ja) * 1995-06-07 1999-08-17 デューク・ユニバーシティ 酸化体脱除剤
WO1997006830A1 (en) * 1995-08-17 1997-02-27 Monsanto Company Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands
CA2183834C (en) * 1995-08-22 2003-09-09 Hiroshi Maeda Antihypertensive agents containing pyrazolopyrimidine derivatives
CN1225631A (zh) * 1996-03-13 1999-08-11 孟山都公司 有歧化过氧化物催化剂效果的含氮大环配位体锰或铁配合物的生物缀合物
CA2309154C (en) 1997-11-03 2010-02-16 Duke University Substituted porphyrins
ES2257858T3 (es) * 1998-04-24 2006-08-01 Duke University Porfirinas sustituidas.
US6632808B1 (en) 1998-08-11 2003-10-14 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of amyloid formation
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
WO2000023568A2 (en) * 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
US6210392B1 (en) * 1999-01-15 2001-04-03 Interventional Technologies, Inc. Method for treating a wall of a blood vessel
US6695830B2 (en) * 1999-01-15 2004-02-24 Scimed Life Systems, Inc. Method for delivering medication into an arterial wall for prevention of restenosis
CA2359116C (en) * 1999-01-25 2009-03-17 National Jewish Medical And Research Center Substituted porphyrins
IT1306716B1 (it) * 1999-06-21 2001-10-02 Mendes S U R L Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori.
SE9903985D0 (sv) * 1999-11-03 1999-11-03 Aga Ab Use of nitric oxide
FR2806911B1 (fr) * 2000-03-28 2003-01-10 Univ Rene Descartes Utilisation de mimetiques de la sod dans le traitement d'insuffisances hepatocellulaires
US6403788B1 (en) 2000-07-11 2002-06-11 Eukarion, Inc. Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species
EP1367998A4 (de) * 2000-09-15 2004-03-17 Scripps Research Inst Verfahren und zusammensetzungen, die die wasserstoffperoxid- und -superoxidproduktion durch antikörper betreffen
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
JP2004520380A (ja) * 2001-01-19 2004-07-08 ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター 癌治療本出願は、２００１年１月１９日に出願の仮出願番号第６０／２６２，３９０号の優先権を主張し、その全ての内容は、参照により本願明細書に援用したものとする。
AU2002236861A1 (en) * 2001-01-26 2002-08-06 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
JP2005508864A (ja) * 2001-06-01 2005-04-07 ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター 糖尿病の治療、または移植術における使用、または免疫寛容の誘導のためのオキシダントスカベンジャー
US20040157280A1 (en) * 2001-09-17 2004-08-12 Paul Wentworth Antibody mediated ozone generation
US20040116350A1 (en) * 2001-09-17 2004-06-17 Paul Wentworth Jr Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
US20050129680A1 (en) * 2001-09-17 2005-06-16 Paul Wentworth Antimicrobial activity of antibodies
AU2003216400A1 (en) 2002-02-22 2003-09-09 The Curators Of The University Of Missouri Compounds for treatment of copper overload
AU2003237500A1 (en) * 2002-06-07 2003-12-22 Duke University Substituted porphyrins
BR0315628A (pt) * 2002-11-14 2005-08-23 Novartis Ag Geração de ozÈnio mediada por anticorpo ou neutrófilo
ES2694574T3 (es) 2003-05-01 2018-12-21 Cornell Research Foundation, Inc. Método y complejos portadores para suministrar moléculas a células
US7432369B2 (en) 2004-03-29 2008-10-07 Inotek Pharmaceuticals Corporation Pyridyl-substituted porphyrin compounds and methods of use thereof
US8697120B2 (en) * 2006-05-01 2014-04-15 Johns Hopkins University Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
WO2009140408A2 (en) 2008-05-13 2009-11-19 University Of Kansas Metal abstraction peptide (map) tag and associated methods
WO2010016965A2 (en) 2008-05-23 2010-02-11 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
JP4891367B2 (ja) 2009-05-21 2012-03-07 トヨタ自動車株式会社 溶媒組成物
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
CN104190927B (zh) 2014-08-11 2016-05-18 苏州大学 一种同步送粉空间激光加工与三维成形方法及装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4758422A (en) * 1985-01-04 1988-07-19 Salutar Inc. Ferrioxamine paramagnetic contrast agents for MR imaging
AU587472B2 (en) * 1985-05-22 1989-08-17 Liposome Technology, Inc. Liposome inhalation method and system
DK402785D0 (da) * 1985-09-03 1985-09-03 Syn Tek Ab Fremgangsmaade til fremstilling af et enzym
DE3854872D1 (de) * 1987-03-14 1996-02-22 Boehringer Ingelheim Int Humane Mangan-Superoxiddismutase (hMn-SOD)
US5227405A (en) * 1987-03-31 1993-07-13 Duke University Superoxide dismutase mimic
US5223538A (en) * 1987-03-31 1993-06-29 Duke University Superoxide dismutase mimic
US5171680A (en) * 1988-06-14 1992-12-15 Chiron Corporation Superoxide dismutase analogs having novel binding properties
WO1990010694A1 (en) * 1989-03-06 1990-09-20 Suntory Limited New superoxide dismutase
DK455789D0 (da) * 1989-09-15 1989-09-15 Symbicom Ab Polypeptid
EP0424033A3 (en) * 1989-10-19 1991-07-31 Pola Chemical Industries Inc External skin preparation
EP0462836A3 (en) * 1990-06-20 1992-08-26 Mitsui Toatsu Chemicals, Inc. Recombinant vector plasmid capable of expressing human manganese superoxide dismutase, and process of producing this enzyme
US5217966A (en) * 1990-09-13 1993-06-08 The Regents Of The University Of California Synthetic drug molecules that mimic metalloenzymes
US5202317A (en) * 1990-09-13 1993-04-13 The Regents Of The University Of California Synthetic drug molecules that mimic metalloenzymes
WO1992007935A1 (en) * 1990-11-01 1992-05-14 The Scripps Research Institute Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
EP0524161A1 (de) * 1991-07-19 1993-01-20 Monsanto Company Mangan-Komplexe mit Stickstoff enthaltenden makrozyklischen Liganden, wirksam als Superoxiddismutase-Katalysatoren
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
WO2000023568A2 (en) * 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
CA2359116C (en) * 1999-01-25 2009-03-17 National Jewish Medical And Research Center Substituted porphyrins
US6448239B1 (en) * 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof

Also Published As

Publication number Publication date
EP1442747A1 (de) 2004-08-04
ES2237753T3 (es) 2005-08-01
US5747026A (en) 1998-05-05
EP0723398A4 (de) 1999-03-24
CA2174236C (en) 2008-02-12
WO1995010185A1 (en) 1995-04-20
JPH09505805A (ja) 1997-06-10
DE69434313D1 (de) 2005-04-28
AU702596B2 (en) 1999-02-25
DE69434313T2 (de) 2006-03-30
EP0723398B1 (de) 2005-03-23
AU7976394A (en) 1995-05-04
CA2174236A1 (en) 1995-04-20
EP0723398A1 (de) 1996-07-31

Similar Documents

Publication Publication Date Title
ATE291351T1 (de) Superoxiddismutase memetika
ATE238307T1 (de) Substituierte porphyrinen
DE69635304D1 (de) Faenger fuer oxidantien
BR0007720A (pt) Porfirinas substituìdas
DK1071474T3 (da) Substituerede porphyriner
CA2135575A1 (fr) Composition cosmetique contenant en tant qu'agent reducteur un n-mercapto-alkyl alcanediamide ou l'un de ses sels cosmetiquement acceptable
MX9700557A (es) Dihidrobenzofuranos.
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DK0754176T3 (da) Hidtil ukendte carbamater og urinstoffer som modifikatorer for multidrugsresistens
ZA951617B (en) Antithrombotic agents.
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
MX9709240A (es) Fenilpiridazinonas.
ATE271390T1 (de) Verwendung von azithromycin zur topischen behandlung von augeninfektionen
MX9401175A (es) Inhibidores de la acetilcolinesterasa sililada.
TR200001745T2 (tr) Keton peroksit türevleri, bunların hazırlanması ve kullanılması
WO1996031208A3 (de) Verwendung von substituierten piperidin- oder pyrrolidinverbindungen zur behandlung von sigma-rezeptor modulierten krankheiten
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
DE59403966D1 (de) Hydroxymethylfurazancarbonsäurederivate und ihre verwendung in der behandlung von kardiovaskulären erkrankungen
LV11593A (lv) Dimetikona pielietojums aizcietejumu arstesana
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
ATE222255T1 (de) 14-substituierte marcfortine und derivate als antiparasitäre mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties